Pulmonary thromboembolism in criticall ill COVID-19 patients

Michele Scialpi Sara Scialp Irene Piscioli Giovanni Scalera Fernando Longo

PII: S1201-9712(20)30272-1

DOI: https://doi.org/doi:10.1016/j.ijid.2020.04.056

Reference: IJID 4144

To appear in: International Journal of Infectious Diseases

Received Date: 13 April 2020

Revised Date: 19 April 2020

Accepted Date: 21 April 2020

Please cite this article as: Scialpi M, Scialp S, Piscioli I, Scalera G, Longo F, Pulmonary thromboembolism in criticall ill COVID-19 patients, *International Journal of Infectious Diseases* (2020), doi: https://doi.org/10.1016/j.ijid.2020.04.056

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier.



Pulmonary thromboembolism in criticall ill COVID-19 patients

Michele Scialpi[†], Sara Scialp^, Irene Piscioli*, Giovanni Scalera§, Fernando Longo¶

[†]Section of Diagnostic, Department of Surgical and Biomedical Sciences, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy

^ Department of Anaestesia and Intensive Care , University Hospital Pisa, Italy *Division of Radiology, Budrio Hospital, Bologna Italy

§Section of Radiology1 Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy

¶ Department of Anaestesia and Intensive Care, University Hospital Perugia, Italy

Correspondence to: Michele Scialpi, MD, Full Professor of Radiology, Perugia University, S.M. della Misericordia Hospital, S. Andrea delle Fratte, 06156 Perugia, Italy.Tel.: +39 075.5783507, Fax: +39 0755783488, e-mail: michelescialpi1@gmail.com

Highlights

- COVID-19 in criticall ill patients causes death not only for pneumonia but also for multiple organ injuries;
- in critical ill COVID-19 patients with pneumonia, pulmonary thromboembolism may be considered;
- in critical ill COVID-19 patients contrast-enhanced CT of the chest is mandatory to assess parenchymal patterns and to diagnose pulmonary thromboembolism

Dear Editor,

the outbreak of novel Coronavirus disease 2019 (COVID-19) in the city of Wuhan, Hubei province of China, has been declared a pandemic by the World Health Organization (WHO) on March 21st, and has since then forced the scientific community to consider two fundamental aspects: first off, SARS-CoV-2 does not only cause pneumonia and second, the death of many critical ill patients is caused by multiple organ failure (involving the heart, liver, kidneys, blood and immune system). Therefore, attention should be paid to potential multiorgan injury and its prevention should be part of the treatment of COVID-19 especially in critically ill patients (1).

Since the first report of Dr Zhu et al. (2) on COVID-19 pneumonia, several studies have been published highlighting the role of chest Computed Tomography (CT) in detecting typical and atypical parenchymal patterns and in assessing the evolution over the time of COVID-19 pneumonia (3,4). Other findings include enlarged subsegmental pulmonary vessels in 59%-89% of COVID-19 pneumonia cases (5,6) which could be related to pro-inflammatory factors or hyperemia (7,8), Pulmonary thrombombolism (PTE) has been reported by CT in patients with COVID-19 pneumonia with high D-dimer levels (9,10) and in COVID-19 patient with normal D-dimer level, without strong predisposing risk factors for venous thrombo-embolism (VTE) (11).

At the moment it is unclear whether hospitalized patients with COVID-19 have a greater risk of VTE than other patients who have chest infections and elevated D-dimer values (12). Critically ill patients are likely to be at increased risk of VTE, especially if they become immobilised on critical care. However The risk of VTE must be assessed in all patients admitted to the hospital, and prevention should be administered to all high-risk patients according to international guidance on thromboprophylaxis (13). Lee

at al (14) in a observational study suggest that up to 5-10% of patients with COVID-19

infection who require mechanical ventilation have acute pulmonary embolism and/or

deep venous thrombosis.

Coronavirus determines direct endothelial cells injury of the microvessels with

subsequent release of damaged endothelial cells into the bloodstream (15); severe

COVID-19 patients are often immobile and present with an acute inflammatory state

that leads to hypercoagulability. Therefore PTE may be considered in COVID-19

patients with sudden onset of oxygenation deterioration, respiratory distress and

reduced blood pressure. This might be supported by the alterated D-dimer values, and

although it is true that D-dimer is a non specific acute phase reactant, elevated D-dimer

values have been used to identify those severe COVID-19 patients at increased risk of

VTE (16).

CT plays a critical role in the pathological pulmonary changes observed in severe

and critical COVID-19 patients (17). Contrast-enhanced CT of the chest is mandatory

to assess parenchymal patterns and their evolution over time. Moreover, CT allows the

diagnosis of PTE, a common finding in severe COVID-19, guiding correct treatment

after a careful evaluation of the patient's pre-existing comorbidities.

In COVID-19 infection, which is associated with a high morbidity and mortality rate,

largerly due to respiratory failure, a pathophysiological role of PE and the usefulness of

contrast-enhanced CT in diagnosis may be considered.

Conflict of Interest

No conflict of interest to declare.

Funding Source

3

None.

Ethical Approval

Approval was not required.

References

- 1. Wang T, Du Z, Zhu F et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. Thelancet, 21 march 2020, vol 395, 10228.
- 2. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-733.
- 1. Chung M, Bernheim A, Mei X, et al. CT imaging features of 2019 novel coronavirus (2019- nCoV). Radiology 2020; 295:202–207.
- Pan F, Ye T, Sun P, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology 2020:200370. doi: 10.1148/radiol.2020200370. Published February 1, 2020. Accessed February 13, 2020.
- Bai HX, Hsieh B, Xiong Z et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology 2020:200823. doi: 0.1148/radiol.2020200823.
- Albarello F, Pianura E, Di Stefano F et al. 2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation. Int J Infect Dis 2020;93:192-197.
- 5. Ye Z, Zhang Y, Wang Y et al. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol 2020. doi: 10.1007/s00330-020-06801-0.

- 6. Li W, Moore MJ, Vasilieva N et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426(6965):450-454.
- 7. Danzi GB(Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020 Mar 30. pii: ehaa254.
- 8. Xie Y, Wang X Yang P, Zhang S. COVID-19 Complicated by Acute Pulmonary Embolism Radiology: Cardiothoracic Imaging Vol. 2, No. 2 Online:Mar 16 2020.
- Chen J et al. Findings of Acute Pulmonary Embolism in COVID-19 Patients. Lancet 2020.
- 10. Darzi AJ, Karam SG, Charide R et. Prognostic factors for VTE and Bleeding in Hospitalized Medical Patients: a systematic review and meta-analysis. Blood. 2020 Feb 24. pii: blood.2019003603. doi: 10.1182/blood.2019003603.
- 11. Anderson D, Morgano GP, Bennett C et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. *Blood Adv* (2019) 3 (23): 3898–3944.
- 12.Lee A, deSancho M, Pai M et al) COVID-19 and Pulmonary embolism: frequentlyasked questions. Americam Society of haematology, COVID- resources. Update 10 april 2020.
- 13.Zhang W, Zhao Y, Zhang F et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China Clin Immunol 2020 Mar 25 : 108393.
- 14. Spyropoulos AC, Lipardi C, Xu J et al. Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely III

Medical Population for Extended Thromboprophylaxis. TH Open. 2020 Mar 13;4(1):e59- e65. doi: 10.1055/s-0040-1705137.

15.An P, Ye Y, Chen M Chen Y Fan W, Wang Y. Management strategy of novel coronavirus (COVID-19) pneumonia in the radiology department: a Chinese experience. Diagn Interv Radiol 2020; DOI 10.5152/dir.2020. 20167.

Authors contributions

- Writing manuscript: MS, SS;
- Editing Manuscript: MS, SS, IP, GBS, FL;
- Literature research: IP, GBS, FL.

The Authors declare no conflicts of interest associated for the manuscript entiltled "Pulmonary thromboembolism in criticall ill COVID-19 patients".